SKEMA/EADA
28.9.2021 19:48:11 CEST | Business Wire | Press release
SKEMA Business School and EADA Business School have signed an agreement to launch a new joint double-degree BBA programme "SKEMA X EADA Global BBA" in Barcelona, where EADA operates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006004/en/
Through this alliance, SKEMA intends to develop a new European base from EADA's Barcelona campus. EADA will benefit from the presence of SKEMA’s campuses in five continents. At the same time, the two schools also aim to open this new four-year post-baccalaureate programme to candidates from Spanish-speaking countries.
"This post-baccalaureate double-degree programme is a new opportunity to develop SKEMA’s brand in the European continent and South America with EADA. It also offers our students in the SKEMA Global BBA – a programme which has 50% international students representing more than 60 different nationalities – the possibility of studying on the EADA campus and immersing themselves in the global city of Barcelona, with its ultra-dynamic economic centre, where they will be able to follow the sustainable innovation specialisation," explains Patrice Houdayer, Director of Programmes, International and Student Life at SKEMA Business School.
"As part of its development, EADA wanted to enter the field of post-baccalaureate BBA programmes, by favouring a partnership with a school that is highly recognised internationally. This is possible thanks to SKEMA, which will design a programme with us that meets the best international BBA standards, and which will confer the degree of bachelor and the visa," says Jordi Diaz, Dean at EADA.
From September 2022, students in the new EADA X SKEMA Global BBA double-degree programme will be able to spend the first two years on the EADA campus in Barcelona, then go on a mobility programme in the third year on one of SKEMA's seven campuses across the world, and then spend their fourth year either in Barcelona or on one of SKEMA's campuses, depending on the specialisation they have chosen.
About SKEMA Business School
With 9,500 students of 120 nationalities and 50,000 graduates in 145 countries, SKEMA Business School is a global school which, through its research, its +70 teaching programmes, its international multi-site structure trains and educates the talents that 21st century businesses need. The school is now present on 7 locations across 5 countries: 3 campuses in France (Lille, Sophia Antipolis, Paris), 1 in China (Suzhou), 1 in the United States (Raleigh), 1 in Brazil (Belo Horizonte) and 1 in South Africa (Cape Town - Stellenbosch).
SKEMA’s Faculty composed of 180 professors is divided into 3 academies (Globalisation, Innovation, Digitalisation). The Research Department has 5 research centres representing the main dimensions of management. The school has also established its Artificial Intelligence research and resource centre in Montreal.
SKEMA Ventures, SKEMA's incubation-acceleration dedicated device, has incubated over 250 projects.
SKEMA is multiaccredited - Equis, AACSB and EFMD Accredited EMBA. Its programmes are recognized in France (Visa, ‘licence’ Degree, Master Degree, RNCP, CGE label), as well as in the United States (Licensing), Brazil (Certificação) and China (Ministry of Education).
www.skema.edu . Follow us on Twitter: @SKEMA_BS
About EADA Business School
EADA Business School Barcelona was founded in 1957 as a private and independent institution. It has EQUIS (EFMD) and AMBA accreditations and is ranked 28th best business school in Europe by the Financial Times, top 45 best schools in Executive Education and its MBA is ranked 21st in Europe and 78th worldwide. With a renovated 4,000m2 campus in the centre of Barcelona and its residential campus in Collbató being the largest in Europe (15 hectares), today its Alumni community is represented by more than 100,000 members of 65 different nationalities and, after 64 years of history, its mission continues to be to promote the professional development and growth of people, as well as the transformation of organisations, in order to contribute to a more just, supportive and sustainable life. The axes on which it supports its learning model are innovation, sustainability and leadership.
www.eada.edu/es . Follow it on LinkedIn : @EADABusinessSchool
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom